Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Corona RemediesNSE:CORONA +0.37%18 EBITDA Margin % is 18.81% as of Mar. 2026, which is 5% above its 10-year median of 17.90. GuruFocus rates NSE:CORONA with a GF Score™ of 18/100. The stock has 3 warning signs investors should review. Among 961 Drug Manufacturers companies, Corona Remedies ranks better than 66.81% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Corona Remedies's EBITDA for the
three
months ended in Mar. 2026 was ₹664 Mil. Corona Remedies's Revenue for the
three
months ended in Mar. 2026 was ₹3,531 Mil. Therefore, Corona Remedies's EBITDA margin for the quarter that ended in Mar. 2026 was 18.81%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Corona Remedies EBITDA Margin % Related Terms
Corona Remedies EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Corona Remedies's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:CORONA vs LLY, JNJ, ABBV: EBITDA Margin % Comparison
For the Drug Manufacturers - General subindustry, Corona Remedies's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corona Remedies EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Corona Remedies's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Corona Remedies's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corona Remedies (NSE:CORONA) has a EBITDA Margin % of 18.81% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Corona Remedies and its competitors. This is near median its historical median of 17.90. Over the past decade, Corona Remedies' EBITDA Margin % has ranged from 15.10 to 20.39. According to the industry distribution chart, Corona Remedies ranks #319 out of 961 companies in the Drug Manufacturers industry, placing it in the top 33.2%.
Is Corona Remedies' EBITDA Margin % too high?
Corona Remedies' current EBITDA Margin % of 18.81% is near median its 10-year median of 17.90. Over the past 10 years, this metric has ranged from a low of 15.10 to a high of 20.39. The Drug Manufacturers industry median EBITDA Margin % is 12.45. Corona Remedies' value of 18.81% is 51.1% above this industry median. Based on the distribution chart, Corona Remedies ranks #319 out of 961 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Corona Remedies has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Corona Remedies' EBITDA Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Corona Remedies ranks #319 out of 961 companies for EBITDA Margin %. This puts Corona Remedies in the upper half of its industry. The industry median EBITDA Margin % is 12.45. Corona Remedies' value of 18.81% is 51.1% above this benchmark. Historically, Corona Remedies' own EBITDA Margin % has ranged from 15.10 to 20.39 over the past decade. While the company's 10-year median is 17.90 vs. the industry median of 12.45, Corona Remedies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.45, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Corona Remedies's current EBITDA Margin % of 18.81% is 51.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Corona Remedies and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Corona Remedies's current EBITDA Margin % is 18.81%, which is near median its own 10-year median of 17.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corona Remedies stock overvalued right now?
Corona Remedies (NSE:CORONA) has a current EBITDA Margin % of 18.81%. The current EBITDA Margin % is 18.81%, which is near median its 10-year median of 17.90 and 51.1% above the Drug Manufacturers industry median of 12.45. Corona Remedies' overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Corona Remedies (NSE:CORONA), the current EBITDA Margin % is 18.81% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Corona Remedies Ltd is mainly engaged in the business of manufacturing, trading and marketing of Pharmaceutical products. It is engaged in developing, manufacturing and marketing products in women's healthcare, cardio-diabetes, pain management, urology and other segments, such as Vitamin Minerals and Nutrients(VMN), gastrointestinal and respiratory therapies. The company's brands are B-29, myoril, Tricium, Cortel, and Obimet. The Company has only one reportable business segment i.e. Pharmaceuticals. The company has presence in India as well as Outside India. The company generates majority of revenue from India.
18GF Score
Get the complete analysis for NSE:CORONA
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:CORONA has been successfully added to your 
